INFERGEN (interferon alfacon-1)
Company: Amgen
Approval Status: Approved October 1997
Treatment for: hepatitis C
Areas: Immunology/Infectious Diseases
General Information
Other Useful Resources
A launch has taken place in the U.S. of Amgen's consensus interferon (interferon alfacon-1, INFERGEN) for the treatment of chronic hepatitis C virus infection.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
